<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00498225</url>
  </required_header>
  <id_info>
    <org_study_id>01023017</org_study_id>
    <nct_id>NCT00498225</nct_id>
  </id_info>
  <brief_title>Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic Cancer</brief_title>
  <acronym>GEST</acronym>
  <official_title>Randomized Phase III Study of Gemcitabine Versus TS-1 Versus Gemcitabine Plus TS-1 in Unresectable Advanced Pancreatic Cancer (With Local Progression or Metastasis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiho Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TTY Biopharm</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Taiho Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with unresectable advanced pancreatic cancer, non-inferiority of TS-1 monotherapy
      and superiority of GEM + TS-1 combination therapy to gemcitabine (GEM) will be verified using
      survival time.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Over all survival(OS)</measure>
    <time_frame>every course for first three courses, then every other course</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival (PFS), response rate (RECIST, if measurable), incidence rate of adverse events, incidence rate of adverse drug reactions, QOL (EQ-5D)</measure>
    <time_frame>adverse events will be collected during treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">834</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine plus TS-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TS-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine plus TS-1</intervention_name>
    <description>Gemcitabine plus TS-1:Gemcitabine was administered i.v. by 1000 mg/m2 at day 1, 8 followed by 2 week rest as 1 course. TS-1 was co-administered orally at 40 mg/m2 twice daily for 14 days with a rest period of 1 week as one course.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-1</intervention_name>
    <description>TS-1 was administered orally at 40 mg/m2 twice daily for 28 days with a rest period of 2week as one course.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine was administered i.v. by 1000 mg/m2 at day 1, 8, 15 followed by 2 week rest as 1 course.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pancreatic carcinoma histologically determined to be adenocarcinoma or adenosquamous
             carcinoma.

          -  Advanced unresectable pancreatic (including pancreatic cancer with local progression
             and recurrent pancreatic cancer).Presence/absence of measurable lesions is not
             considered. Patients with measurable lesions must undergo diagnostic imaging tests
             within 28 days before registration.

          -  Patients with no previous treatment (radiotherapy,chemotherapy etc) for pancreatic
             cancer, except resection. Intra-operative radiotherapy during resection of pancreatic
             cancer will be permitted, although registration must occur at least 4 weeks after the
             radiotherapy. Patients that have undergone preoperative/postoperative adjuvant
             chemotherapy may be enrolled if relapse is diagnosed beyond week 24 after the final
             administration (on day 169 when the day following the final day is set as day 1).

          -  Age: 20 years to 79 years.

          -  ECOG Performance Status (PS) of 0 or 1.

          -  Sufficient function of major organs as defined below. (The following criteria are
             satisfied in laboratory tests conducted within 14 days before registration. Laboratory
             tests conducted 2 weeks before registration (on the same weekday) will be included.)
             White blood cell count≥ 3500/mm3 Neutrophil count≥ 2000/mm3 Hemoglobin≥9.0 g/dL
             Platelet count≥100000/mm3 Total bilirubin≤ 2.0 mg/dL* *≤ 3.0 mg/dL in patients treated
             by biliary drainage for obstructive jaundice. AST and ALT≤ 150 U/L Serum
             creatinine≤1.2 mg/dL Creatinine clearance≥50mL/min.** **Measured values will be used
             if available. Otherwise, values calculated by the Cockcroft-Gault method will be
             used.Formula for estimation:body weight (kg) x [140 - age (years) / 72 x serum
             creatinine (mg/dL)] *Estimated value will be multiplied by 0.85 for females.

          -  Able to take capsules orally.

          -  No clinically abnormal ECG findings within 28 days (4 weeks)before registration.

          -  Voluntarily signed the written consent form.

        Exclusion Criteria:

          -  Pulmonary fibrosis or interstitial pneumonia (to be confirmed by chest X-ray within 28
             days before enrollment).

          -  Watery diarrhoea.

          -  Active infections (e.g. patients with pyrexia of 38°C or greater), excluding viral
             hepatitis.

          -  Serious complications (e.g. heart failure, renal failure,hepatic failure, haemorrhagic
             peptic ulcer, intestinal paralysis, intestinal obstruction or poorly controlled
             diabetes).

          -  Moderate or severe (requiring drainage) ascites or pleural effusion requiring
             treatment.

          -  Metastasis in the CNS.

          -  Active double cancer (synchronous double cancer or asynchronous double cancer with
             disease-free duration of 3 years or less). Carcinoma in situ and lesions of
             intramucosal carcinoma will not be included in active double cancer and will be
             permitted for registration.

          -  Patients under treatment with flucytosine, phenytoin or warfarin potassium.

          -  Pregnant females, possibly pregnant females, females wishing to become pregnant and
             nursing mothers. Males that are currently attempting to produce a pregnancy.

          -  Severe mental disorder.

          -  Judged ineligible by physicians for participation in the study from a safety
             viewpoint.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takuji Okusaka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung-Ho Memorial Hospital, Kaohsiung Medical University</name>
      <address>
        <city>No.100, Tzyou 1st Rd., Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital, Kaohsiung</name>
      <address>
        <city>No.123, Ta-Pei Rd., Niao-Sung Hsiang, Kaohsiung Hsien</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>No.135, Nanxiao St., Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>No.138, Sheng Li Road,Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>No.2, Yuh-Der Rd.,Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>No.201, Sec. 2, Shih-Pai road, Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chi Mei Medical Center Liou Ying Campus</name>
      <address>
        <city>No.201, Taikang Village, Liou Ying Township, Tainan</city>
        <zip>736</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital, Lonkou</name>
      <address>
        <city>No.5, Fu-Hsing St. Kuei Shan Hsiang, Taoyuan Hsien</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>No.7, Chung San South Road, Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chi Mei Medical Center</name>
      <address>
        <city>No.901, Chung Hwa Rd., Yong Kang city, Tainan</city>
        <zip>710</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital, Taipei</name>
      <address>
        <city>No.92, Sec. 2, Zhongshan N. Rd., Taipei</city>
        <zip>104</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997 Jun;15(6):2403-13.</citation>
    <PMID>9196156</PMID>
  </reference>
  <reference>
    <citation>Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C. An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology. 2005;68(2-3):171-8. Epub 2005 Jul 4.</citation>
    <PMID>16006754</PMID>
  </reference>
  <reference>
    <citation>Ueno H, Okusaka T, Ikeda M, Ishiguro Y, Morizane C, Matsubara J, Furuse J, Ishii H, Nagase M, Nakachi K. A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer. Oncology. 2005;69(5):421-7. Epub 2005 Nov 25.</citation>
    <PMID>16319514</PMID>
  </reference>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2007</study_first_submitted>
  <study_first_submitted_qc>July 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2007</study_first_posted>
  <last_update_submitted>November 1, 2012</last_update_submitted>
  <last_update_submitted_qc>November 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

